
Redeye Initiates Coverage of Lipum

Redeye initiates coverage of Lipum, a Swedish biotech company offering a unique approach to the USD 60 billion-plus inflammatory diseases market. Lipum is establishing a unique platform which will be the key driver for continued development and long-term growth. With lead candidate, SOL-116, now entering the clinic, we argue it has the potential to mark a new era in rheumatoid arthritis (RA). Should it manage to deliver encouraging clinical data, it could catch the eye of large industry players.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Redeye Initiates Coverage of Lipum